Advanced Gastric Cancer
Conditions
Interventions
treatment group:Apatinib+FLOT
Sponsors
Liaoning Cancer Hospital and Institute
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with histologically confirmed locally advanced adenocarcinoma of the stomach or EGJ; A clinical III stage was undertaken by ultrasonic endoscope/contrast-enhanced CT/MR without surgical contraindications; Age ranges from 18 to 75 years; Eastern Cooperative Oncology Group(ECOG) performance status of one or less; No prior antineoplastic therapy; Patients were tolerated of surgical III grade; WBC>4.0×10/L,ANC>1.5 ×10^9/L, Hb=100g/L, PLT=100×10^9/L, serumbilirubin=1.5×ULN, AST, ALT=2.5ULN, Cr=1.0×ULN; No other current or previous malignancy; Abide by the plan; Offer informed consent in writing and understand no loss profit after quiting; the expected survival =6 mouths
Exclusion criteria
Exclusion criteria: Distant metastasis and unresectable; Other current or previous malignancy, but curative skin basal cell carcinoma and carcinoma in situ of cervix were excluded; Her-2 positive and accept the related therapy; Known hypersensitivity to FU, leucovorin, oxaliplatin, docetaxel; Pregnant or breast feeding; Having antineoplastic therapy; Serious or no uncontrolled medical diseases and infection; Major organ failure such decompensated heart, lung, liver, kidney failure; With surgical contraindications; Gastrointestinal bleeding and/or coagulation disorders;Entered other study; HBV or HCV was active?; Peripheral neuropathy of NCI grade=2 at baseline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| resectable rate(R0,R1,R2);pathologic complete response;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-Free Time;Overall Survival, OS;recurrence rate; | — |
Countries
China
Contacts
Public ContactZheng Zhichao
Outcome results
None listed